All In Biotech

Drug Trial Radar · NCT04720261

Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP

Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult Acquired Thrombotic Thrombocytopenic Purpura: A Phase II, Multicenter Non-inferiority Single-arm Study.

Last checked: Nov 20, 2026Latest source record: Feb 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

58

Actual

Start

Apr 26, 2021

Primary completion

May 16, 2023

Study completion May 16, 2023

Sponsor

Lead sponsor
University Hospital, RouenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to evaluate the efficacy of a personalized caplacizumab regimen based on ADAMTS13 activity monitoring in adult acquired thrombotic thrombocytopenic purpura (aTTP): This study is a phase II, prospective, multicenter non-inferiority single-arm study.

Conditions

  • Thrombotic Thrombocytopenic Purpura, Acquired

Interventions

  • CaplacizumabDrug

    Analyse of ADAMTS13 activity in patients with aTTP treated with Caplacizumab in order to help adapting the treatment with caplacizumab in TTP patients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the feasibility of a personalized caplacizumab regimen in aTTP based on ADAMTS13 activity monitoring assessed by a composite criteria including mortality, refractoriness and/or exacerbation at 30 days post-PE treatmentTime frame: 30 days post-PE treatment

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • Chu Amiens

    Amiens, France

  • Chu Angers

    Angers, France

  • Chu Besancon

    Besançon, France

  • Chu Bordeaux

    Bordeaux, France

  • CHU CAEN

    Caen, France

  • Chu Clermont-Ferrand

    Clermont-Ferrand, France

  • Chu Lille

    Lille, France

  • Chu Limoges

    Limoges, France

  • Ch Edouard Herriot

    Lyon, France

  • Ap-Hm Hopital de La Conception

    Marseille, France

  • Chu Montpellier

    Montpellier, France

  • Chu Nancy

    Nancy, France

  • Chu Nantes

    Nantes, France

  • Ah-Hp Hopital Saint Louis

    Paris, France

  • Ap-Hp Hopital de Cochin

    Paris, France

  • Ap-Hp Hopital de Necker

    Paris, France

  • Ap-Hp Hopital de St Antoine

    Paris, France

  • Chu Reims

    Reims, France

  • Chu Rennes

    Rennes, France

  • Chu Rouen

    Rouen, France

  • Reunion Sud

    Saint-Paul, France

  • Chu Tours

    Tours, France

  • Ch Valenciennes

    Valenciennes, France

  • Fort de France

    Fort-de-France, Martinique

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.